The Gut Microbiome and Chemotherapy: What the Research Says About Your Outcome

By Dr. Lena Suhaila ND, FABNO | Integrative Oncology | Functional Medicine

There is a question that does not get asked often enough in oncology consultations, and it is one I find myself returning to constantly: what is living inside you, and does it have a vote in how your treatment goes?

It should be asked more, because the answer, increasingly, is yes. And for me, this is not a new fascination. Microbiology was my first degree, long before I came to naturopathic medicine and integrative oncology, and the thing that captivated me then was exactly this: that invisible organisms could shape so much of what happens inside a human body. What I could not have predicted is that decades later, that same area of science would sit right at the centre of how I understand cancer, treatment, and the conditions that allow healing to happen.

Over the last decade, microbiome research has moved from the periphery of biomedicine toward something closer to its core. We have known for a long time that the human gut harbours trillions of microorganisms, bacteria, fungi, archaea, and viruses, all coexisting in a dynamic, interconnected ecosystem that influences digestion, hormonal signalling, immune function, and neurological health. What we are only now beginning to understand in earnest is how profoundly this microbial community shapes what happens when cancer treatment enters the picture. The implications are not subtle. And if you are someone navigating a cancer diagnosis, or supporting someone who is, this is information that deserves to be part of your picture.

First, a Question Worth Asking

Why do two people with the same cancer, the same stage, the same treatment protocol, and the same oncology team end up with such different outcomes? Oncologists will tell you it is tumour biology, genetics, age, performance status, and all of that is true. None of it is the whole story. What is rarely included in that conversation is the ecological state of the patient’s gut when treatment begins, yet that is precisely where some of the most compelling research in cancer medicine is now pointing.

The Gut Is Not a Passive Bystander

It is worth pausing on what the microbiome actually does before exploring what it does in the context of cancer treatment, because there is still a tendency, even among educated patients, to think of gut bacteria primarily in terms of digestion and bloating. That framing is about two decades out of date.

The gut microbiome is the primary training ground for the immune system. Approximately 70 percent of immune tissue in the human body is located in and around the gastrointestinal tract. The microbes that populate that space are in constant, sophisticated dialogue with immune cells, shaping their development, their tolerance thresholds, their inflammatory set points, and their ability to mount responses to foreign threats, including cancer cells.

Short-chain fatty acids produced by bacterial fermentation of dietary fibre, particularly butyrate, propionate, and acetate, act as signalling molecules that regulate immune cell behaviour across the entire body, not just the gut. Butyrate in particular has been shown to influence regulatory T cells, the cells responsible for modulating immune responses and preventing both underreaction and overreaction. The balance of these microbial metabolites is not incidental to immune competence. It is central to it. When that microbial ecosystem is diverse, stable, and populated by the right organisms, the immune system tends to behave well. When it is disrupted, whether by antibiotics, poor diet, chronic stress, or the treatment itself, the downstream immunological consequences are measurable and clinically significant.

What the Research Actually Shows

In 2018, three studies published in the same issue of Science changed the conversation in oncology permanently. Researchers at the MD Anderson Cancer Center, the Institut Gustave Roussy in France, and the University of Chicago independently found that the composition of a patient’s gut microbiome predicted their response to immunotherapy, specifically checkpoint inhibitors targeting the PD-1 and PD-L1 pathways.

This was not a marginal finding. Patients with higher gut microbial diversity, and specifically higher abundance of certain bacterial species, were significantly more likely to respond to treatment. Patients whose microbiomes were dominated by less favourable organisms, or who had received antibiotics in the months preceding treatment, showed substantially poorer outcomes.

The French study found that patients who had taken antibiotics before starting immunotherapy had a median overall survival of 11.5 months compared to 20.6 months in those who had not. That is not a rounding error. That is a gap that should be part of every informed conversation before a patient begins treatment, and in most oncology offices, it simply is not.

The organisms that kept appearing in the research as beneficial were telling. Akkermansia muciniphila, a bacterium that thrives in a well-nourished gut and plays a key role in maintaining the integrity of the intestinal lining, was consistently associated with better immunotherapy response. Bifidobacterium longum, Faecalibacterium prausnitzii, and members of the Lachnospiraceae family also appeared repeatedly in the profiles of responders. What these organisms have in common is that they flourish when the gut is well fed with diverse plant-based fibres, that they produce anti-inflammatory metabolites, and that they help maintain a gut lining that is not chronically permeable. They are, in other words, the bacteria that reflect a terrain that has been cared for.

The Antibiotic Question Nobody Is Raising

Antibiotics are a routine part of cancer care, used to manage infections during chemotherapy-induced immunosuppression, and often appropriately so. But their collateral impact on the microbiome is significant and is rarely addressed as part of the clinical plan.

A broad-spectrum antibiotic course does not selectively eliminate pathogenic bacteria. It remodels the entire ecosystem, often wiping out exactly the organisms associated with immune competence and treatment response. Recovery from a single course of antibiotics can take months, and some species may not return to baseline at all without active intervention. This is not an argument against using antibiotics when they are clinically necessary. It is an argument for thinking carefully about timing, for using the narrowest spectrum agent appropriate to the situation, for not prescribing prophylactically out of habit, and for actively supporting microbiome restoration during and after treatment. None of this is radical. It simply requires the gut to be included in the clinical conversation rather than treated as an afterthought.

The same applies to proton pump inhibitors, routinely prescribed to manage gastrointestinal side effects of chemotherapy. These drugs alter the pH of the upper gastrointestinal tract and measurably shift microbial composition. When they are genuinely needed, that is a clinical decision worth making. The point is to make it with the full picture in view.

Chemotherapy, the Gut Lining, and What Happens When the Barrier Breaks Down

Chemotherapy does not discriminate between rapidly dividing cancer cells and rapidly dividing healthy cells. The cells lining the gastrointestinal tract divide quickly and are consequently among the first casualties of cytotoxic treatment. This is the mechanism behind mucositis, the painful inflammation of the gut lining that many patients experience, and it is also the mechanism behind something more systemic and less visible: increased intestinal permeability.

When the gut lining is compromised, the tight junctions between intestinal epithelial cells loosen, and bacterial products, particularly lipopolysaccharides from gram-negative bacteria, can translocate into systemic circulation. This triggers an inflammatory cascade that is not confined to the gut. It feeds into systemic inflammation, immune dysregulation, and a biological environment that is less hospitable to recovery.

The integrity of the gut lining is not self-sustaining. It is actively maintained by the microbial community around it. Akkermansia muciniphila is named for its relationship to the mucus layer, the protective coating that sits between the gut contents and the epithelium. Organisms like Faecalibacterium prausnitzii produce butyrate, which is the primary fuel source for colonocytes, the cells lining the colon. A gut that is microbially depleted is a gut that struggles to repair itself precisely when repair matters most.

Your Nervous System Has More to Do With This Than You Might Think

This is a part of the picture that I find endlessly compelling, and it connects everything in a way that most people have not considered.

Your gut and your brain are linked by the vagus nerve, the longest nerve in the body and the primary channel of the parasympathetic nervous system. This connection runs in both directions simultaneously. Your gut influences your brain, and your brain influences your gut, but what matters here is that the state of your nervous system directly shapes the environment your gut bacteria are living in.

When the nervous system is chronically in a state of threat, stuck in sympathetic activation as it so often is for someone navigating a serious illness, stress hormones alter gut motility, shift the pH of the gastrointestinal tract, reduce blood flow to digestive tissue, and change the mucosal immune environment in ways that favour inflammatory organisms over the ones associated with health and immune competence. The research on this is mechanistically clear, and a 2011 study published in Brain, Behavior, and Immunity demonstrated directly that social stress altered the structure of the intestinal microbiota in measurable ways.

Conversely, when the nervous system is genuinely regulated, when the body has access to the parasympathetic rest and digest state, the conditions in the gut shift. Motility normalises, the mucosal immune environment becomes more hospitable, and the terrain becomes one in which health-supporting organisms are more likely to thrive. This is precisely why nervous system regulation is not a peripheral concern in my practice. It is a biological intervention with downstream effects that reach all the way into the microbial ecosystem. Helping someone move out of chronic threat response changes the internal conditions that their microbiome, and by extension their immune system, is operating within. Polyvagal theory gives us a framework for understanding this that is grounded in physiology, not metaphor, and it is one I draw on consistently in clinical work with people going through cancer treatment.

Fecal Microbiota Transplantation: The Frontier of What Is Coming

If microbial composition influences treatment response, can you change the microbiome of a non-responder and turn that around? That is the question driving some of the most provocative current research in oncology.

Fecal microbiota transplantation involves transferring stool from a carefully selected donor into the gastrointestinal tract of a recipient to reshape the recipient’s microbial ecosystem. In the context of recurrent Clostridioides difficile infection, this approach has proven remarkably effective and is now accepted clinical practice. In oncology, the results are early but significant. A 2021 study published in Science by researchers at Sheba Medical Center in Israel showed that fecal microbiota transplantation from patients who had responded to anti-PD-1 immunotherapy could convert some previous non-responders into responders. A parallel study from MD Anderson published in Nature Medicine that same year showed similar results in melanoma patients who had failed immunotherapy.

These are not claims of a cure. They are proof of concept that the microbial environment is not fixed, that it can be deliberately shifted, and that those shifts have measurable downstream effects on immune function and treatment efficacy. The clinical translation of this will take time. The biological rationale is already solid.

What Does This Mean Practically?

The first thing to understand is that microbiome diversity does not emerge from taking a probiotic. It emerges from the long-term dietary, lifestyle, and environmental conditions that determine which organisms can survive and thrive in your gut. A targeted supplement can be supportive and in specific clinical contexts very useful, but it is not a substitute for the substrate that feeds a healthy ecosystem.

Dietary diversity, specifically the variety of plant foods consumed, is the most robustly evidenced driver of gut microbial diversity. Research from the American Gut Project found that individuals who consumed 30 or more different plant species per week had significantly more diverse microbiomes than those consuming 10 or fewer. This does not require a radical overhaul. It requires attention and intention, consistently applied.

Fermented foods, traditionally fermented and not pasteurised after fermentation, introduce live organisms and have been shown to increase microbial diversity and reduce markers of systemic inflammation. A 2021 Stanford study published in Cell found that a high-fermented food diet increased microbial diversity and reduced inflammatory markers more than a high-fibre diet alone, though both have a role and they work better together than apart.

And then there is the nervous system, which brings us back to what I said earlier. Stress, sleep deprivation, and circadian disruption all measurably alter gut microbial composition through their effects on motility, immune signalling, and the mucosal environment. Practices that genuinely support parasympathetic tone are not lifestyle additions. They are part of the biological picture of how a healthy microbiome is maintained, and they belong in the clinical conversation alongside diet and supplementation.

A Note on Testing

Gut microbiome testing has become widely available and varies considerably in quality. Comprehensive stool analysis using validated PCR-based methodology, which can identify organisms beyond what culture-based approaches detect, can provide genuinely useful clinical information. But a result showing low Akkermansia or depleted Bifidobacterium is meaningful only in context. Without that context, it tends to produce anxiety without direction. If you want to understand your microbiome as part of a broader integrative picture, that conversation belongs inside a clinical framework where the results actually inform the plan.

The Larger Point

Cancer treatment is not happening in isolation from the biological terrain it is entering. That terrain includes your immune system, your metabolic environment, your nervous system, and the trillions of microorganisms that are modulating all of the above simultaneously.

The emerging microbiome research does not suggest that good bacteria will cure cancer. It suggests something more nuanced and ultimately more empowering: that the conditions inside your body are not neutral, that they influence how treatment behaves, and that there are meaningful, evidence-informed ways to shift those conditions in your favour. The question worth asking is not whether this matters. The research has answered that. The question is whether you are including it in your picture of what healing actually requires.

If you are navigating a cancer diagnosis and want to understand what a thorough integrative assessment looks like, including how your gut terrain, immune function, nervous system regulation, and metabolic health fit together into a coherent clinical picture, this is exactly the kind of conversation I am here to have.

Book a Consultation

References

Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1 based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-97.

Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.

Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104-108.

Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602-609.

Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602.

Sonnenburg JL, Sonnenburg ED. Vulnerability of the industrialized microbiota. Science. 2019;366(6464):eaaw9255.

Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137-4153.

McDonald D, Hyde E, Debelius JW, et al. American Gut: an open platform for citizen science microbiome research. mSystems. 2018;3(3):e00031-18.

Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine. 2017;23(1):107-113.

Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971-976.

Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535(7610):65-74.

Bailey MT, Dowd SE, Galley JD, et al. Exposure to a social stressor alters the structure of the intestinal microbiota. Brain, Behavior, and Immunity. 2011;25(3):397-407.

Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiological Reviews. 2019;99(4):1877-2013.